# US 2003/0083288 A1 · Screening methods and therapeutic treatments for pigment dispersion syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083288 A1
- Document ID: US20030083288A1
- Status: Published application
- Kind: A1
- Application number: 10/005,906
- Filed: 2001-10-26
- Published: 2003-05-01
- Earliest claimed: 2001-10-26
- Assignees: The Jackson Laboratory
- Inventors: Michael G. Anderson; Simon W.M. John
- Web page: https://patentgrep.com/patent/US20030083288A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are methods for identifying a genetic disorder associated with pigment dispersion syndrome or pigmentary glaucoma in a mammal. The methods include analytical characterization of a nucleic sample from an afflicted individual, and comparison of this characterization with an otherwise identical characterization of a nucleic acid sample from a non-afflicted individual. Also disclosed are methods for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma. Such methods include the study of melanocyte cell cultures from afflicted and/or non-afflicted individuals, and the effect of test compounds on such cultures. Also disclosed are methods for identifying a therapeutic compound through the use of a mouse model system. Therapeutic methods are also encompassed within the scope of the present disclosure.

## Claims

### Claim 1

A method for identifying a genetic disorder associated with pigment dispersion syndrome or pigmentary glaucoma in a mammal, the method comprising:
a) providing a nucleic acid sample from a mammal suspected of being afflicted with pigment dispersion syndrome or pigmentary glaucoma, the nucleic acid sample comprising nucleotides associated with the glycoprotein (transmembrane) nmb gene and the tyrosinase-related protein 1 gene;
b) performing analytical characterization of the nucleic acid sample, or sequences derived from the nucleic acid sample, by analytical techniques capable of resolving single nucleic acid changes; and
c) comparing the analytical characterization of step b), with the results of an otherwise identical analytical characterization carried out on nucleic acid samples from a mammalian population known to be non-afflicted by pigment dispersion syndrome or pigmentary glaucoma, the identification of one or more nucleic acid changes in the nucleic acid of the mammal of step a), as compared with the nucleic acid sequences of the population of step c), being indicative of a genetic disorder associated with pigment dispersion syndrome or pigmentary glaucoma.

### Claim 2 (depends on 1)

The method of claim 1 wherein the nucleic acid sample of step a) is genomic DNA, mRNA or total RNA.

### Claim 3 (depends on 1)

The method of claim 1 wherein the step b) nucleic acid sample, or sequences derived from the nucleic acid sample, are genomic DNA, cDNA or mRNA.

### Claim 4 (depends on 1)

The method of claim 1 wherein the analytical technique of step b) is DNA sequence analysis.

### Claim 5 (depends on 1)

The method of claim 1 wherein the analytical technique of step b) comprises the identification of the creation or destruction of a restriction enzyme recognition sequence.

### Claim 6 (depends on 5)

The method of claim 5 wherein the analytical technique is restriction fragment length polymorphism analysis.

### Claim 7 (depends on 1)

The method of claim 1 wherein the analytical technique of step b) comprises the detection of specific hybridization of an oligonucleotide probe to the nucleic acid or sequences encoded by the nucleic acid, under stringent hybridization conditions.

### Claim 8 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 9 (depends on 1)

The method of claim 1 wherein the mammal is a mouse.

### Claim 10 (depends on 1)

The method of claim 1 wherein the mammal is a horse.

### Claim 11 (depends on 1)

The method of claim 1 wherein the mammal is a canine.

### Claim 12

A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
a) establishing a cell culture from melanocytes (i.e., melanin-producing cells) isolated from a mammal;
b) contacting the cell culture of step a) with a test compound to be assayed for the ability to decrease melanin production in the melanocytes of the cell culture;
c) incubating the cell culture of step b) under conditions appropriate for cell growth and division; and
d) identifying a compound having the ability to decrease melanin production in the melanocytes of the cell culture by comparison of the incubated culture of step c) with an otherwise identical culture containing no test compound.

### Claim 13 (depends on 12)

The method of claim 12 wherein the mammal of step a) is known to be afflicted with pigment dispersion syndrome or pigmentary glaucoma.

### Claim 14 (depends on 12)

The method of claim 12 wherein the method is carried out in parallel with a plurality of individual cell cultures, each individual cell culture being incubated with a unique test compound.

### Claim 15 (depends on 14)

The method of claim 14 wherein the plurality of individual cell cultures are contained in the wells of a multi-welled plate.

### Claim 16 (depends on 12)

The method of claim 12 wherein the mammal is a human.

### Claim 17 (depends on 12)

The method of claim 12 wherein the mammal is a mouse.

### Claim 18 (depends on 12)

The method of claim 12 wherein the mammal is a horse.

### Claim 19 (depends on 12)

The method of claim 12 wherein the mammal is a canine.

### Claim 20

A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
a) providing a cell culture of melanocytes (i.e., melanin-producing cells) isolated from a mammal known to be afflicted with pigment dispersion syndrome or pigmentary glaucoma;
b) determining base line information for the cell culture of step a);
c) providing a cell culture of melanocytes (i.e., melanin-producing cells) isolated from a mammal known to be non-afflicted with pigment dispersion syndrome or pigmentary glaucoma;
d) determining base line information for the cell culture of step c); and
e) contacting the cell culture of step a) with a test compound and identifying any changes in base line information away from that determined in step b) and toward that determined in step d).

### Claim 21 (depends on 20)

The method of claim 20 wherein the baseline information is selected from the group consisting of: cell counts over time; radioactive thymidine incorporation; levels of quinones in cells and/or culture medium; levels of oxidative damage to DNA, protein and lipid; cellular morphology indicative of cellular stress involving apoptosis and/or necrosis.

### Claim 22

A method for identifying a compound useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma, the method comprising:
a) providing a mouse model having one or more mutations in the glycoprotein (transmembrane) nmb gene, or the tyrosinase-related protein 1 gene, or both genes, the mutations resulting in a form of pigmentary glaucoma;
b) administering a test compound to the mouse of step a); and
c) assaying for decreased pigment dispersion and decreased initiation and progression of pigmentary glaucoma in the mouse as an indication that the administered test compound is useful in the therapeutic treatment of pigment dispersion syndrome or pigmentary glaucoma.

### Claim 23 (depends on 22)

The method of claim 22 wherein the test compound is administered directly to the eye as a suspension in an eye drop formulation.

### Claim 24 (depends on 22)

The method of claim 22 wherein the test compound is administered orally.

### Claim 25 (depends on 22)

The method of claim 22 wherein the mode of administration of the test compound is administered intravenous, subconjunctival, subcutaneous or interperitoneal.

### Claim 26

A therapeutic method for treating a mammal afflicted with pigment dispersion syndrome or pigmentary glaucoma, the method comprising administering to the mammal a therapeutically effective amount of a compound which reduces melanin production in the iris.

### Claim 27 (depends on 20)

A therapeutic method for treating a mammal afflicted with pigment dispersion syndrome or pigmentary glaucoma, the method comprising administering to the mammal a therapeutically effective amount of a compound identified by the method of claim 20.

### Claim 28 (depends on 22)

A therapeutic method for treating a mammal afflicted with pigment dispersion syndrome or pigmentary glaucoma, the method comprising administering to the mammal a therapeutically effective amount of a compound identified by the method of claim 22.

### Claim 29

An oligonucleotide which hybridizes specifically to a mutant form of the glycoprotein (transmembrane) nmb gene under stringent hybridization conditions, the mutant form of the glycoprotein (transmembrane) nmb gene being linked with pigment dispersion syndrome or pigmentary glaucoma.

### Claim 30

An oligonucleotide which hybridizes specifically to a mutant form of the tyrosinase-related protein 1 gene under stringent hybridization conditions, the mutant form of the tyrosinase-related protein 1 gene being linked with pigment dispersion syndrome or pigmentary glaucoma.
